NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET

Core Insights - NeOnc Technologies Holdings, Inc. is advancing transformative treatments for brain and central nervous system cancers and is featured in a live interview with financial commentator Kenny Polcari [1][4] - The company executed a Sub-License Agreement with its Abu Dhabi subsidiary, NuroCure, as part of a $50 million strategic partnership with Quazar Investment, aimed at expanding its market presence in the UAE and broader GCC and MENA regions [2] - NeOnc was included in the Russell Microcap Index, which aligns with its strategy to attract institutional capital and enhance market liquidity [3] Company Overview - NeOnc Technologies is a clinical-stage life sciences company focused on developing therapeutics for central nervous system conditions, particularly targeting the blood-brain barrier [4] - The company's NEO™ drug development platform has produced novel drug candidates with patent protections extending to 2038, including NEO100™ and NEO212™, which are currently in Phase II clinical trials under FDA Fast-Track and IND status [4]